Compositions including killer innate-like t cells and uses thereof
OwnerMing Li, Chun Chou +4inventors
InventorsMing Li, Chun Chou, Xian Zhang, Saida Dadi, Briana G. Nixon, Jing Zhang
Life of this patent
Estimating the term…
Abstract
Described herein are compositions including killer innate-like T cells (ILTCks), methods for preparing IL TCks for adoptive cell therapy, an methods of using IL TCks to treat cancer. Further, wherein an engineered killer innate-like T cell (ILTCk) comprises a non-endogenous expression vector including a mammalian IL-15 nucleic acid sequence or a mammalian STAT5B nucleic acid sequence is disclosed.
Claims46
An engineered killer innate-like T cell (ILTCk) comprising a non-endogenous expression vector including a mammalian TL-15 nucleic acid sequence or a mammalian STAT5B nucleic acid sequence, wherein the IL-15 nucleic acid sequence or the STAT5B nucleic acid sequence is operably linked to an expression control sequence, optionally wherein the engineered TLC is derived from an autologous donor or an allogenic donor.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An engineered killer innate-like T cell (ILTCk) comprising a chimeric antigen receptor (CAR) that binds to a tumor antigen, wherein the CAR comprises (i) an extracellular antigen binding domain that binds to the tumor antigen;
- (ii) a transmembrane domain;
- and (iii) an intracellular domain comprising a truncated cytoplasmic domain of IL-2RβΔ and one or more co-stimulatory domains, optionally wherein the truncated cytoplasmic domain of IL-2RβΔ comprises the amino acid sequence of SEQ ID NO:
- 7.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cancer or inhibiting tumor growth in a subject in need thereof comprising administering to the subject an effective amount of killer innate-like T cells (ILTCks), optionally wherein
- the ILTCks are native ILTCks, genetically engineered ILTCks, or a combination thereof;
- or
- the ILTCks are isolated from a donor subject and/or expanded ex vivo or in vitro:
- or
- the subject harbors tumors with low mutation burden.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.